MRNA technology has saved millions of lives through the swift rollout of COVID-19 vaccines from the likes of Moderna and Pfizer. Now, I-Mab wants to replicate that success on a quest to treat cancer.

AbbVie recently terminated its license and collaboration agreement with I-Mab over its CD47 antibody compounds and products. AbbVie made the decision to end the agreement with the Shanghai-based ...

SK bioscience has entered into a license agreement with Gates MRI to develop and commercialize a treatment for the prevention of RSV infection.

Having first emerged as therapeutics in the 1980s, monoclonal antibodies (mAbs) are the predominant class of recombinant biologic drugs in development. While intravenous (IV) infusion is a frequently ...

Chairman of the Board, Wei Fu, informed the Company of his intent to purchase up to $2,000,000 of the Company's American Depository Shares (ADSs) ROCKVILLE, Md., Jan. 8, 2025 /PRNewswire/ -- I-Mab ...

I-Mab has had a big 12 months, landing an $180 million upfront from AbbVie and delivering a series of readouts from clinical trials. Now, the Chinese biotech is reportedly seeking to build on its ...

MAINZ, Germany & MUNICH--(BUSINESS WIRE)--BioNTech AG, a rapidly growing biotechnology company developing precise and individualized immunotherapies for the treatment of cancer and the prevention of ...

I-Mab announced positive results from a Phase 1b study of its bispecific antibody, givastomig, which targets Claudin 18.2 and 4-1BB for treating Claudin 18.2-positive gastric cancers. The study, ...

Failing to maintain the MAB can lead to penalties, which could range from monthly maintenance fees to, in some cases, account closure. (Image: Freepik) The Monthly Average Balance (MAB) is the average ...